Dec 11, 2019
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue
Dec 07, 2019
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Dec 06, 2019
Cystic Fibrosis Therapeutics Market to Garner $9.27 Bn, Globally, by 2026 at 9.2% CAGR, Says Allied Market Research
Dec 04, 2019
Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2024 - Therapeutics by HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors and Hormone Receptors
Dec 02, 2019
Breast Cancer Diagnostic and Drug Technologies: Global Markets
Nov 29, 2019
Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019
Nov 28, 2019
Global Cystic Fibrosis Drugs Market by Drug Class, Route of Application & Region - Forecast to 2025
Nov 27, 2019
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue
Nov 27, 2019
Cancer Therapeutics Market Size to Reach US$ 176 Bn by 2026
Nov 25, 2019
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
Nov 22, 2019
Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2019
Nov 21, 2019
Visiongain Report Provides Critical Market-led Data on the $68bn Gastrointestinal Therapeutics Market
Nov 20, 2019
Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology
Nov 13, 2019
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
Nov 13, 2019
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue
Nov 12, 2019
AbbVie Prices $30 Billion of Senior Unsecured Notes
Nov 08, 2019
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue
Nov 06, 2019
AbbVie Announces Launch of Private Offering of Senior Unsecured Notes
Nov 06, 2019
Global HIV Drugs Market Report 2019-2025: Market is Projected to Grow $6.3 Billion
Nov 06, 2019
Global Cancer Therapeutics Market to 2023 with Focus on Recurrent and Metastatic Divisions - Profiles of AbbVie, Biogen, GSK, Eli Lilly and Co., Merck & Co. and Pfizer